All 27 patients with a BCR::ABL1 transcript received first-line treatment with the tyrosine kinase inhibitor (TKI) imatinib, either in addition to conventional induction chemotherapy (according to the recommendations for younger ALL patients) or as monotherapy in induction therapy (according to the recommendations for elderly ALL patients) (Table 2). The gene discussed is BCR; the disease is acute lymphoblastic leukemia.